Mg Magnesiumsulfatheptahydrat (Magnesium Sulfate Heptahydrate)

The compound releases magnesium ions that act as cofactors for many enzymes, stabilize cell membranes, and antagonise calcium at voltage‑gated channels. This results in vasodilation, reduced neuromuscular excitability, and anti‑arrhythmic activity while replenishing depleted magnesium stores.

The specific dose and infusion rate are determined by the prescribing clinician based on the indication, patient weight, renal function and clinical response. Healthcare professionals should follow local guidelines and product labeling when prescribing.

Safety data in pregnancy are limited; the drug is used when the potential maternal benefit outweighs any possible risk to the fetus, particularly for eclampsia management. Breastfeeding considerations should be discussed with a healthcare provider, as magnesium can be excreted in milk.

Enquiries are submitted via the product page on gnhindia.com, where the required quantity is entered. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Magnesium sulfate heptahydrate is the most widely used injectable magnesium salt, offering rapid bioavailability and predictable pharmacokinetics. Compared with oral magnesium salts, it provides faster correction of severe deficiency and is preferred in acute settings such as eclampsia or life‑threatening arrhythmias.

The product should be stored at 2‑8 °C in a refrigerator, protected from light. It must not be frozen or shaken vigorously. Once removed from refrigeration, use within the time frame specified in the product label.

It is administered by intramuscular or intravenous injection under aseptic conditions. The route, infusion speed and total dose are determined by the treating physician according to the clinical indication and patient-specific factors.

Serious risks include respiratory depression, severe hypotension, hypermagnesemia leading to neuromuscular weakness or cardiac arrest, and rare anaphylactic reactions. Continuous monitoring of vital signs and serum magnesium levels is essential during high‑dose therapy.

Patients with known hypersensitivity to magnesium sulfate, severe renal failure without appropriate monitoring, and those with existing profound hypotension or heart block should not receive this medication unless benefits clearly outweigh risks.